Executive Chairman of the Board · USANA HEALTH SCIENCES INC (USNA)

Kevin Guest

A named executive officer of USANA HEALTH SCIENCES in every fiscal year CompBrief holds from FY2016 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$3,911,856

Salary $851,472Stock awards $2,836,324

FY2022: $3,745,259

1st of 7 named executive officers at Usana Health Sciences by FY2023 total.

7 named officers on file for USANA HEALTH SCIENCES, FY2023

Kevin Guest’s pay file — $29

  • 8 fiscal years of pay, line by line
  • 6 equity grants, each cited to its filing
  • USNA’s disclosed peer group of 15 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how USANA HEALTH SCIENCES’s whole pay program stands against its peers

  • USANA HEALTH SCIENCES’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on USNA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 22, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Kevin Guest’s full pay file as a PDF — free

More than this page: up to 10 years of Kevin’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Kevin Guest compensation by year

USANA HEALTH SCIENCES Summary Compensation Table · all 8 fiscal years held
In US dollars, as USANA HEALTH SCIENCES reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Salary$626,628$811,317$820,769$859,654$921,937$914,806$942,250$851,472
Bonus$0$58,613$0$0$0$0$0$0
Stock awards$0$754,769$1,318,333$2,769,545$2,316,993$2,386,513$2,458,135$2,836,324
Option awards$0$0$0$0$0$0$0$0
Non-equity incentive$306,923$428,542$770,450$518,828$711,505$598,146$278,152$164,729
Pension and deferred compensation$0$0$0$0$0$0$0$0
All other$9,275$9,450$9,625$9,800$9,975$10,150$66,722$59,331
Total$942,826$2,062,691$2,919,177$4,157,827$3,960,411$3,909,615$3,745,259$3,911,856

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: USANA HEALTH SCIENCES INC DEF 14A filed March 22, 2024, accession 0000896264-24-000119, and prior-year filings.

How this page was built: the USANA HEALTH SCIENCES INC filed document, accession 0000896264-24-000119. Every figure is read from that document and cited to the page and table it appears in. Filed March 22, 2024.

$943K
$2.1M
$2.9M
$4.2M
$4.0M
$3.9M
$3.7M
$3.9M
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
SalaryBonusNon-equity incentiveStock awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU48,245$2,585,932—
RSU19,804$1,061,494—
RSU16,409$879,522—
RSU14,007$750,775—
PSU10,584$423,876—
RSU4,596$246,346—
Option49,228—$63.02

Per the Outstanding Equity Awards at Fiscal Year-End table in USANA HEALTH SCIENCES INC's FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

26 Form 4 lines since the FY2023 proxy (filed March 22, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-02-27Exercise or conversion derivative—7,856$0.00127,206
2026-02-27Exercise or conversion—7,856—48,709
2026-02-27Tax withholding—3,328$21.5245,381
2026-02-19Grant or award derivative—82,726$0.00135,062
2026-02-08Exercise or conversion derivative—4,425$0.0052,336
2026-02-08Exercise or conversion—4,425—42,728
2026-02-08Tax withholding—1,875$21.3440,853
2026-02-07Tax withholding—2,796$21.3438,303

The 8 most recent of 26 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

USANA HEALTH SCIENCES’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Kevin Guest · this pageExecutive Chairman of the Board$3,911,856
Jim BrownChief Executive Officer & President (former)$2,472,017
G. Douglas HekkingChief Financial Officer$1,469,101
Walter NootChief Operating Officer$1,417,490
Joshua FoukasChief Legal Officer & General Counsel$1,292,741
Daniel Macuga Jr.Chief Communications & Marketing Officer$1,151,549
Brent NeidigChief Commercial Officer$1,045,689

Board service

USANA HEALTH SCIENCES board · FY2024–FY2025
Director compensation in US dollars, as USANA HEALTH SCIENCES reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025—$900,012$0$1,035,785$1,935,797
FY2024$0$900,045—$920,768$1,820,813

Each year as the company reported it in USANA HEALTH SCIENCES's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: USANA HEALTH SCIENCES pays directors a $91,400 cash retainer and $127,027 in equity. As stated in USANA HEALTH SCIENCES's FY2025 proxy.

The full USANA HEALTH SCIENCES compensation record

free company brief

This page is one person within USANA HEALTH SCIENCES's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the USANA HEALTH SCIENCES proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are USANA HEALTH SCIENCES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kevin Guest's compensation dossier · One-time report. No refunds.